Public Profile

Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 1996, the company has made significant strides in developing innovative therapies, particularly in the areas of gastrointestinal and ophthalmic disorders. Sucampo is renowned for its flagship product, Amitiza (lubiprostone), which offers unique benefits for patients suffering from chronic constipation and irritable bowel syndrome. With a strong focus on research and development, Sucampo has established a solid market position, recognised for its commitment to improving patient outcomes through advanced pharmaceutical solutions. The company operates primarily in North America and has expanded its reach into international markets, further solidifying its reputation as a leader in specialty pharmaceuticals.

DitchCarbon Score

How does Sucampo Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

27

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Sucampo Pharmaceuticals, Inc.'s score of 27 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

0%

Let us know if this data was useful to you

Sucampo Pharmaceuticals, Inc.'s reported carbon emissions

Sucampo Pharmaceuticals, Inc., headquartered in the US, currently does not have available carbon emissions data or specific reduction targets. Without documented emissions figures or commitments to climate initiatives, it is challenging to assess their environmental impact or sustainability efforts. In the pharmaceutical industry, companies are increasingly focusing on reducing their carbon footprints and committing to science-based targets to mitigate climate change. However, Sucampo Pharmaceuticals has not publicly outlined any such commitments or initiatives at this time.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Sucampo Pharmaceuticals, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Sucampo Pharmaceuticals, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Sucampo Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Synergy Health Limited

GB
Health and social work services (85)
Updated 3 months ago
DitchCarbon Score

Shire plc

IE
Health and social work services (85)
Updated 3 months ago
DitchCarbon Score

Hi-Tech Pharmacal Co., Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Braintree Laboratories, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Chiesi USA, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Bausch Health Cos

CA
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers